Nautilus Biotechnology (NAUT) Cash & Equivalents (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Cash & Equivalents data on file, last reported at $14.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 56.0% year-over-year to $14.6 million; the trailing twelve-month figure through Mar 2026 stood at $14.6 million (down 56.0% YoY), and the FY2025 full-year result was $12.4 million, down 55.19% from the prior year.
• Cash & Equivalents advanced to $14.6 million in Q1 2026, from $12.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $210.4 million in Q2 2022 to a low of $4.4 million in Q3 2024.
• A 5-year average of $68.1 million and a median of $33.2 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 27556.78% in 2022 and tumbled 94.05% in 2024, its largest moves.
• Tracing NAUT's Cash & Equivalents over 5 years: stood at $114.5 million in 2022, then sank by 83.06% to $19.4 million in 2023, then jumped by 42.53% to $27.6 million in 2024, then plunged by 55.19% to $12.4 million in 2025, then rose by 18.07% to $14.6 million in 2026.
• Business Quant data shows NAUT's Cash & Equivalents at $14.6 million in Q1 2026, $12.4 million in Q4 2025, and $23.9 million in Q3 2025.